SynthesisFrontiers in neurology2024

Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.

Yuying Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.